In-Silico medication of vitiligo by targeting 6AAH protein and riboflavin Ligand

Depigmentation of the skin is a primary symptom of the vitiligo disorder. By reducing their self-esteem and causing them psychological distress, it lowers patients’ quality of life. The study made use of a number of computational tools, including Cyto Hubba, BioVia Discovery Studio through, Open babel, Drug bank, Avogadro, Auto dock, and Protein-Interaction Ligand profiler. The interaction between 6AAH and (Myristic acid, Heptadecanoic acid, Riboflavin, Propanol, 2,6-Dimethyl-7-octene-2,3,6-trio1) has been examined in this study using Cyto Hubba and PILP clustering interactions, followed by Molecular Docking of Protein and Ligand. Due to its polygenic nature, vitiligo is frequently associated with a number of autoimmune or autoinflammatory disorders, including thyroid disease, psoriasis, atopic dermatitis, diabetes mellitus, and pernicious anaemia. Hence, it is conceivable to think about riboflavin as a possible drug for Vitiligo treatment. The findings imply that riboflavin laboratory tests reveal its inhibitory potential on skin depigmentation